Journal
NUTRITION
Volume 27, Issue 1, Pages 3-20Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nut.2010.07.021
Keywords
Glucose; Ketones; Brain; Aging; Alzheimer's disease; PET; Insulin; Cognition; Mitochondria
Categories
Funding
- Canada Research Chairs secretariat (SCC)
- CIHR
- NSERC
- CFI
- AFMNet
- Universite de Sherbrooke (Faculty of Medicine and Health Sciences and the Department of Medicine)
- Sherbrooke Molecular Imaging Center
- Etienne-Le Bel Clinical Research Centre
- Research Center on Aging
- FQRNT
- Intramural Program of the National Institute on Aging, National Institutes of Health, USA
- NATIONAL INSTITUTE ON AGING [ZIAAG000148, Z01AG000148] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Lower brain glucose metabolism is present before the onset of clinically measurable cognitive decline in two groups of people at risk of Alzheimer's disease-carriers of apolipoprotein E4, and in those with a maternal family history of AD. Supported by emerging evidence from in vitro and animal studies, these reports suggest that brain hypometabolism may precede and therefore contribute to the neuropathologic cascade leading to cognitive decline in AD. The reason brain hypometabolism develops is unclear but may include defects in brain glucose transport, disrupted glycolysis, and/or impaired mitochondrial function. Methodologic issues presently preclude knowing with certainty whether or not aging in the absence of cognitive impairment is necessarily associated with lower brain glucose metabolism. Nevertheless, aging appears to increase the risk of deteriorating systemic control of glucose utilization, which, in turn, may increase the risk of declining brain glucose uptake, at least in some brain regions. A contributing role of deteriorating glucose availability to or metabolism by the brain in AD does not exclude the opposite effect, i.e., that neurodegenerative processes in AD further decrease brain glucose metabolism because of reduced synaptic functionality and hence reduced energy needs, thereby completing a vicious cycle. Strategies to reduce the risk of AD by breaking this cycle should aim to (1) improve insulin sensitivity by improving systemic glucose utilization, or (2) bypass deteriorating brain glucose metabolism using approaches that safely induce mild, sustainable ketonemia. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available